Skip Navigation


JAC Advance Access originally published online on May 5, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/6/1039    most recent
dkh248v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Koeth, L. M.
Right arrow Articles by Dubreuil, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koeth, L. M.
Right arrow Articles by Dubreuil, L. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 1039-1044
© 2004 The British Society for Antimicrobial Chemotherapy

Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents

Laura M. Koeth1,*, Caryn E. Good1, Peter C. Appelbaum2, Ellie J. C. Goldstein3, Arne C. Rodloff4, Marina Claros4 and Luc J. Dubreuil5

1 Laboratory Specialists, Inc., Cleveland, OH; 2 M. S. Hershey Medical Center, Hershey, PA; 3 R. M. Alden Research Laboratory, Santa Monica, CA, USA; 4 Institute für Medizinische Mikrobiologie und Infektionsepidemiologie der Universität Leipzig, Leipzig, Germany; 5 ADRINORD, Lille, France

Received 27 October 2003; returned 14 January 2004; revised 12 March 2004; accepted 22 March 2004

In vitro susceptibility data were collected for co-amoxiclav and other antimicrobial agents against 1297 recent anaerobe isolates collected in Europe and the USA. The co-amoxiclav (amoxicillin/clavulanic acid) MIC50/90s (amoxicillin/clavulanic acid concentration in a ratio of 2:1, expressed in terms of amoxicillin concentration in mg/L) were 0.5/4 for Bacteroides fragilis, <=0.125/1 for Prevotella species, <=0.125/0.25 for Fusobacterium nucleatum, 0.5/1 for Eikenella corrodens, 0.25/8 for Peptostreptococcus anaerobius, <=0.125/0.5 for Micromonas (Peptostreptococcus) micros, <=0.25/0.5 for Fingoldia (Peptostreptococcus) magna, and <=0.125/0.125 for Porphyromonas species. The co-amoxiclav susceptibility rate for B. fragilis was 94.6%, for P. anaerobius 84.3% and for all other species tested 100%. These data indicate that co-amoxiclav remains an effective drug for the antimicrobial treatment and prophylaxis of many anaerobic infections. Among the comparator drugs, metronidazole was very active against all bacterial species (>96% susceptible) except E. corrodens (MIC50/90 of >32/>64 mg/L), which is a capnophilic organism. Imipenem was also highly active against all species (>98% susceptible). Levofloxacin and clindamycin were the least potent agents tested, particularly against Bacteroides, Prevotella and Peptostreptococcus (levofloxacin susceptibility rates: Bacteroides 72.7%, Prevotella 71.5%, F. magna 72.4%; clindamycin susceptibility rates: Bacteroides 79.5%, Prevotella 92.1%, F. magna 84.7%).

Keywords: amoxicillin/clavulanic acid, anaerobes, susceptibility data

* Corresponding author. Tel: +1-440-835-4458; Fax: +1-440-835-5786; E-mail: amdlmk{at}aol.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
C.-Y. Liu, Y.-T. Huang, C.-H. Liao, L.-C. Yen, H.-Y. Lin, and P.-R. Hsueh
Increasing Trends in Antimicrobial Resistance among Clinically Important Anaerobes and Bacteroides fragilis Isolates Causing Nosocomial Infections: Emerging Resistance to Carbapenems
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3161 - 3168.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Kononen, A. Bryk, P. Niemi, and A. Kanervo-Nordstrom
Antimicrobial Susceptibilities of Peptostreptococcus anaerobius and the Newly Described Peptostreptococcus stomatis Isolated from Various Human Sources
Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2205 - 2207.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M.-F. Odou, C. Muller, L. Calvet, and L. Dubreuil
In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections
J. Antimicrob. Chemother., April 1, 2007; 59(4): 646 - 651.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
A. Katsandri, J. Papaparaskevas, A. Pantazatou, G. L. Petrikkos, G. Thomopoulos, D. P. Houhoula, and A. Avlamis
Two Cases of Infections Due to Multidrug-Resistant Bacteroides fragilis Group Strains
J. Clin. Microbiol., September 1, 2006; 44(9): 3465 - 3467.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
L. Boyanova, R. Kolarov, G. Gergova, E. Deliverska, J. Madjarov, M. Marinov, and I. Mitov
Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria.
J. Med. Microbiol., September 1, 2006; 55(Pt 9): 1285 - 1289.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.